REGN insider trading
NasdaqGS HealthcareREGENERON PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.
Company website: www.regeneron.com
REGN insider activity at a glance
FilingIQ has scored 3,826 insider transactions for REGN since Feb 20, 2015. The most recent filing in our index is dated May 1, 2026.
Across the full history, 126 open-market purchases
and 2,492 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on REGN insider trades is 57.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest REGN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding REGN
Politicians who have traded REGN
Frequently asked
- How many insider trades does FilingIQ track for REGN?
- FilingIQ tracks 3,826 Form 4 insider transactions for REGN (REGENERON PHARMACEUTICALS, INC.), covering filings from Feb 20, 2015 onwards. 47 of those were filed in the last 90 days.
- Are REGN insiders net buyers or net sellers?
- Across the full Form 4 history for REGN, 126 transactions (3%) were open-market purchases and 2,492 (65%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does REGN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is REGN in?
- REGENERON PHARMACEUTICALS, INC. (REGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $78.78B.
Methodology & sources
Every REGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.